Virtus LifeSci Biotech Clinical Trials ETF Rating $22.64 +0.46 (+2.07%) Closing price 04:10 PM EasternExtended Trading$22.65 +0.01 (+0.04%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsRatingsShort InterestBuy This Stock Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.85Holdings in BBC have an aggregate rating of Moderate Buy based on 201 analyst ratings issued in the past year covering 24 companies (26.0% of the portfolio).BBC Aggregate Price Target$22.64High Prediction$22.64Average Prediction$22.64Low Prediction$22.64Holdings in BBC have an aggregate price target of $22.64 and a range of $22.64 to $22.64 covering 24 companies (26.0% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy12 Buy rating(s)Moderate Buy9 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 24 BBC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.51%SANASana Biotechnology$3.60+3.7%3.2358 of 5 stars3.00$8.00 122.2%61.38%VERVVerve Therapeutics$11.133.1123 of 5 stars2.33$14.57 30.9%91.36%COGTCogent Biosciences$11.77-0.8%3.4735 of 5 stars2.82$18.70 58.9%11Positive News1.27%NTLAIntellia Therapeutics$10.13-0.8%4.5246 of 5 stars2.58$29.05 186.8%191.23%ABCLAbCellera Biologics$4.30+3.1%2.2948 of 5 stars3.00$8.00 86.0%6Gap Up1.20%TERNTerns Pharmaceuticals$6.76+7.3%3.7352 of 5 stars2.60$15.63 131.1%5News Coverage1.07%RAPPRapport Therapeutics$14.93+4.3%1.7179 of 5 stars3.00$29.50 97.6%2Insider Trade1.06%PHVSPharvaris$23.35+1.5%2.629 of 5 stars2.83$35.60 52.5%6News CoverageAnalyst UpgradeShort Interest ↓Analyst Revision1.06%CNTACentessa Pharmaceuticals$17.53+1.4%2.1787 of 5 stars3.00$28.10 60.3%11Analyst Revision1.04%MNMDMind Medicine (MindMed)$9.82+3.9%2.8344 of 5 stars3.22$24.71 151.7%9Positive News1.04%SMMTSummit Therapeutics$26.01+0.5%2.3947 of 5 stars2.63$32.85 26.3%16News CoverageAnalyst Forecast1.04%TNGXTango Therapeutics$7.01+3.9%1.9437 of 5 stars3.00$10.50 49.8%5Analyst ForecastInsider Trade1.02%NUVBNuvation Bio$2.74+0.9%2.2791 of 5 stars3.17$7.33 168.1%61.02%GHRSGH Research$12.99+1.6%3.0054 of 5 stars2.88$32.00 146.3%81.01%PRTAProthena$8.56+0.5%3.2738 of 5 stars2.33$30.25 253.4%91.00%RXRXRecursion Pharmaceuticals$4.78+0.2%2.5754 of 5 stars2.33$7.00 46.4%6News CoverageInsider Trade0.98%MAZEMaze Therapeutics$13.23-1.9%N/A3.29$25.60 93.5%7Positive NewsAnalyst Revision0.97%BEAMBeam Therapeutics$16.01-0.3%2.2086 of 5 stars3.07$48.45 202.7%140.97%PRAXPraxis Precision Medicines$46.38+2.5%1.6214 of 5 stars2.75$85.88 85.2%80.96%AUTLAutolus Therapeutics$1.75+1.2%3.0473 of 5 stars3.00$9.12 421.1%5Gap Up0.96%MLTXMoonLake Immunotherapeutics$54.17+0.1%1.6102 of 5 stars2.78$74.43 37.4%90.95%KALVKalVista Pharmaceuticals$12.96+0.4%3.9913 of 5 stars3.11$26.29 102.8%90.94%SRRKScholar Rock$34.59+0.6%4.4087 of 5 stars3.20$45.75 32.3%10News CoverageAnalyst Forecast0.94%RNACCartesian Therapeutics$10.96-1.0%2.3478 of 5 stars2.80$40.00 265.0%5 This page (NYSEARCA:BBC) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access